A Phase 1/2 interventional study of Omaveloxolone Capsules (2.5 mg/capsule) and Ipilimumab (3 mg/kg) in Melanoma, Unresectable (Stage III) Melanoma and Metastatic (Stage IV) Melanoma, sponsored by Biogen. Completed at 10 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-04.
Sponsored by Biogen · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 2,049 studies in Melanoma with a site in United States — 243 open to participants now, 440 under way, 32 of them phase 3. Melanoma · United States.
Among the 2,049 studies in Melanoma with a site in United States, this one is the 808th largest by enrollment of the 1,749 interventional ones that give a count, is one of 81 that started in 2014, is one of 287 in phase 1/2, and was the 1,035th registered.
3,373 studies on the registry are indexed under Melanoma; 580 are open to participants now.
Browse Melanoma studies →243 of the 2,049 studies in Melanoma with a site in United States are open now. Recruiting first, the newest first:
Children's Oncology Group · Sites in United States
Ages up to 25
John Kirkwood · Sites in United States
Ages 18+
University of Wisconsin, Madison · Sites in United States
Ages 18+
H. Lee Moffitt Cancer Center and Research Institute · Sites in United States
Ages 18+ · Healthy volunteers
University of Colorado, Denver · Sites in United States
Ages 55+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 468 Melanoma studies recruiting now, 381 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
2,049 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 934 · Phase 2 907 · Phase 3 115 · Phase 4 11
First in 1991; this study’s year is marked. 81 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 41 is close to the median of 40 across 2,650 interventional studies indexed under Melanoma.
Median enrollment 37 across the 1,749 interventional studies, 156 across the 212 observational. Of the 1,481 that completed or were terminated, 598 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
800 of 2,049 have an industry lead sponsor. The 10 most frequent:
Biogen is the lead sponsor of 512 studies on the registry; 25 are open to participants now.
Of its 100 completed or terminated interventional studies of FDA-regulated products, 50 (50%) have results posted.
Biogen has 4 studies filed under Melanoma — fewer than ten, so there is no comparison to draw.
141 of the studies in Melanoma with a site in United States that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05608291Phase 3Regeneron PharmaceuticalsA Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery | 2027-01-15 |
| NCT05987332Phase 3IDEAYA BiosciencesIDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma | 2027-01-15 |
| NCT06246916Phase 3Regeneron PharmaceuticalsA Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head) | 2027-03-22 |
| NCT01223248Phase 3Memorial Sloan Kettering Cancer CenterRandomized Study Comparing Two Dosing Schedules for Hypofractionated Image-Guided Radiation Therapy | 2027-10 |
| NCT06112314Phase 3Immunocore LtdIMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301) | 2027-10-16 |
Add all 141 to your calendar (.ics) → With an account.
Among the 2,049 studies in Melanoma with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Malignant melanoma is a leading cause of death from cutaneous malignancies, accounting for approximately three-fourths of all skin cancer deaths. For metastatic or unresectable melanomas, standard treatment options include immune checkpoint inhibitors (e.g., ipilimumab and nivolumab) and other therapies, however, approved therapies are rarely curative.
It is now well accepted that tumors are able to evade detection and eradication by the immune system, even though many tumor types, particularly melanoma, are capable of eliciting a strong immune response (Swann, 2007). Substantial mechanistic work in recent years has revealed the key role of myeloid-derived suppressor cells (MDSCs) in masking cancer cells from the immune system, promoting both tumor progression and resistance to cancer immunotherapy. The immune-suppressive effect of MDSCs is dependent on the production of reactive oxygen species (ROS) and reactive nitrogen species (RNS). High levels of these reactive molecules and their by-products, such as nitrotyrosine, have been correlated with poor clinical outcomes in melanoma. Currently available melanoma therapies do not target MDSCs.
In animals, RTA 408 significantly reduces tumor nitrotyrosine burden, inhibits the activity of MDSCs, and augments T-cell anticancer activity at relevant doses. Thus, through inhibition of MDSC activity and suppression of tumor ROS/RNS, RTA 408 may work in combination with T-cell-activating therapeutics such as ipilimumab to enhance the natural immune anticancer response. RTA 408 also has direct anticancer effects via inhibition of NF-kappa B. Chronic activation of NF-kappa B is associated with tumor progression, metastasis, and resistance to therapy.
This proposed study is designed to assess the safety, efficacy, pharmacodynamics, and pharmacokinetics of omaveloxolone (RTA 408) in combination with ipilimumab or nivolumab in patients with unresectable or metastatic melanoma.
In this open-label, multicenter, dose-escalation, Phase 1b/2 study, patients who qualify will receive omaveloxolone (RTA 408) at the assigned dose level in combination with ipilimumab or nivolumab. Patients will receive omaveloxolone (RTA 408) orally once daily for 1 week prior to initiation of ipilimumab or nivolumab. For patients treated with ipilimumab , the run-in period will be followed by omaveloxolone (RTA 408) orally once daily in combination with ipilimumab administered at Weeks 1, 4, 7, and 10. After Week 10, patients will receive maintenance treatment with omaveloxolone (RTA 408) alone once daily. For patients treated with nivolumab, the run-in period will be followed by omaveloxolone (RTA 408) orally once daily in combination with nivolumab administered approximately every two weeks as clinically indicated. Each patient will continue at the assigned omaveloxolone (RTA 408) dose level until disease progression occurs, toxicity requiring discontinuation from study drug (i.e., RTA 408) is experienced, the patient has completed approximately 72 weeks of treatment, the patient is discontinued from the study drug for another reason, or the patient withdraws consent. Patients will return 4 weeks after omaveloxolone (RTA 408) treatment completion for a follow-up visit.
The starting omaveloxolone (RTA 408) dose level for the first dose-escalation cohort in this study has been selected based on available safety and pharmacodynamic data from a Phase 1 study of RTA 408 (NCT02029729). Subsequent cohorts will be enrolled at dose levels based on available safety and PD data from this study, but they will not be greater than 2-fold above the prior dose level.
Phase 1b (dose-escalation): In the phase 1b/2 portion of this study, 12 patients will be enrolled in each dose cohort, with six patients administered omaveloxolone (RTA 408) plus ipilimumab and the remaining six administered rTA 408 plus nivolumab. Subsequent cohorts will assess escalating the doses of omaveloxolone (RTA 408) administered in combination with ipilimumab or nivolumab. Dose escalation decisions will be based on ongoing review of all available safety information for enrolled patients.
Phase 2: The Phase 2 portion of the study may include separate expansion cohorts consisting of patients treated with either of the combination therapies. Each expansion cohort will include an additional 24 patients enrolled at the selected Phase 2 dose level to achieve a total of 30 patients at that omaveloxolone (RTA 408) dose in combination with ipilimumab or nivolumab.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Omaveloxolone (RTA 408) capsules, Dose1 taken orally once daily for 168 weeks, plus ipilimumab (3 mg/kg) administered at weeks 1, 4, 7, and 10.
Drug: Omaveloxolone Capsules (2.5 mg/capsule) · Drug: Ipilimumab (3 mg/kg)
Omaveloxolone (RTA 408) capsules, 10 mg taken orally once daily for 168 weeks, plus ipilimumab (3 mg/kg) administered at weeks 1, 4, 7, and 10.
Drug: Ipilimumab (3 mg/kg) · Drug: Omaveloxolone Capsules (10 mg/capsule)
Omaveloxolone (RTA 408) capsules, 5 mg taken orally once daily for 168 weeks, plus nivolumab (240 mg) administered every two weeks as clinically indicated.
Drug: Omaveloxolone Capsules (2.5 mg/capsule) · Drug: Nivolumab (240 mg)
Omaveloxolone (RTA 408) capsules, 10 mg taken orally once daily for 168 weeks, plus nivolumab (240 mg) administered every two weeks as clinically indicated.
Drug: Nivolumab (240 mg) · Drug: Omaveloxolone Capsules (10 mg/capsule)
Omaveloxolone (RTA 408) capsules, 20 mg taken orally once daily for 168 weeks, plus nivolumab (240 mg) administered every two weeks as clinically indicated.
Drug: Nivolumab (240 mg) · Drug: Omaveloxolone Capsules (10 mg/capsule)
Omaveloxolone (RTA 408) capsules, 100 mg taken orally once daily for 168 weeks, plus nivolumab (240 mg) administered every two weeks as clinically indicated.
Drug: Nivolumab (240 mg) · Drug: Omaveloxolone Capsules (50 mg/capsule)
Omaveloxolone (RTA 408) capsules, 150 mg taken orally once daily for 168 weeks, plus nivolumab (240 mg) administered every two weeks as clinically indicated.
Drug: Nivolumab (240 mg) · Drug: Omaveloxolone Capsules (50 mg/capsule)
Drug page: Omaveloxolone
Capsules containing 2.5 mg of omaveloxolone per capsule to the dosage indicated in the Arm Label
Also known as: RTA 408 Capsules (2.5 mg/capsule)
Drug page: Ipilimumab
Sterile solution containing ipilimumab to be delivered intravenously at 3mg/kg
Also known as: Yervoy
Sterile solution containing nivolumab to be delivered intravenously at 240 mg
Also known as: Opdivo
Drug page: Omaveloxolone
Capsules containing 10 mg of omaveloxolone per capsule to the dosage indicated in the Arm Label
Also known as: RTA 408 Capsules (10 mg/capsule)
Drug page: Omaveloxolone
Capsules containing 50 mg of omaveloxolone per capsule to the dosage indicated in the Arm Label
Also known as: RTA 408 Capsules (50 mg/capsule)
Measure of Efficacy of the Phase 2 Dose of RTA 408 in Combination With Nivolumab Using Overall Response Rate (ORR; Complete Plus Partial Responses) According to RECIST Version 1.1 Criteria
Best overall response rate (ORR) is defined as the proportion of patients with complete or partial tumor size reduction according to RECIST v1.1 criteria. Stable disease is not a component of ORR. Complete response: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. Partial reduction: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. The first occurrence of a response is considered an unconfirmed response. A CR or PR which persists to the next tumor burden assessment is then considered a confirmed response. Confirmed plus unconfirmed best overall response are presented. A subject may be counted twice if best unconfirmed response and best confirmed response are different.
Time frame: From enrollment up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab
| Milestone | Omaveloxolone 5 mg & Ipilimumab | Omaveloxolone 10 mg & Ipilimumab | Omaveloxolone 5 mg & Nivolumab | Omaveloxolone 10 mg & Nivolumab | Omaveloxolone 20 mg & Nivolumab | Omaveloxolone 100 mg & Nivolumab | Omaveloxolone 150 mg & Nivolumab |
|---|---|---|---|---|---|---|---|
| Started | 6 | 6 | 6 | 6 | 6 | 6 | 5 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 6 | 6 | 6 | 6 | 6 | 6 | 5 |
| Withdrew: Adverse event | 1 | 1 | 2 | 0 | 0 | 0 | 0 |
| Withdrew: Progressive disease | 4 | 5 | 4 | 5 | 4 | 5 | 4 |
| Withdrew: Sponsor termination of study | 1 | 0 | 0 | 1 | 2 | 1 | 1 |
Best overall response rate (ORR) is defined as the proportion of patients with complete or partial tumor size reduction according to RECIST v1.1 criteria. Stable disease is not a component of ORR. Complete response: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. Partial reduction: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. The first occurrence of a response is considered an unconfirmed response. A CR or PR which persists to the next tumor burden assessment is then considered a confirmed response. Confirmed plus unconfirmed best overall response are presented. A subject may be counted twice if best unconfirmed response and best confirmed response are different.
| Participants | Omaveloxolone 5 mg & Ipilimumab | Omaveloxolone 10 mg & Ipilimumab | Omaveloxolone 5 mg & Nivolumab | Omaveloxolone 10 mg & Nivolumab | Omaveloxolone 20 mg & Nivolumab | Omaveloxolone 100 mg & Nivolumab | Omaveloxolone 150 mg & Nivolumab |
|---|---|---|---|---|---|---|---|
| Best Overall Responses | 6 | 0 | 5 | 2 | 3 | 3 | 4 |
| Progressive Disease | 3 | 0 | 3 | 0 | 1 | 3 | 2 |
| Stable Disease | 1 | 0 | 1 | 1 | 1 | 1 | 1 |
| Partial Response | 3 | 0 | 0 | 2 | 2 | 0 | 2 |
| Complete Response | 0 | 0 | 1 | 0 | 1 | 0 | 0 |
Collected over Adverse events were reported from time of the first dose of study drug up to the time of disease progression, up to 172 weeks for participants receiving Omaveloxolone in combination with Ipilimumab and 173 weeks for participants receiving Omaveloxolone combination with Nivolumab.. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Omaveloxolone 5 mg & Ipilimumab | 0/6 (0%) | 2/6 (33.3%) | 6/6 (100%) |
| Omaveloxolone 10 mg & Ipilimumab | 0/6 (0%) | 2/6 (33.3%) | 6/6 (100%) |
| Omaveloxolone 5 mg & Nivolumab | 1/6 (16.7%) | 1/6 (16.7%) | 6/6 (100%) |
| Omaveloxolone 10 mg & Nivolumab | 1/6 (16.7%) | 3/6 (50%) | 6/6 (100%) |
| Omaveloxolone 20 mg & Nivolumab | 2/6 (33.3%) | 2/6 (33.3%) | 6/6 (100%) |
| Omaveloxolone 100 mg & Nivolumab | 0/6 (0%) | 2/6 (33.3%) | 6/6 (100%) |
| Omaveloxolone 150 mg & Nivolumab | 1/5 (20%) | 2/5 (40%) | 5/5 (100%) |
| Event | Omaveloxolone 5 mg & Ipilimumab | Omaveloxolone 10 mg & Ipilimumab | Omaveloxolone 5 mg & Nivolumab | Omaveloxolone 10 mg & Nivolumab | Omaveloxolone 20 mg & Nivolumab | Omaveloxolone 100 mg & Nivolumab | Omaveloxolone 150 mg & Nivolumab |
|---|---|---|---|---|---|---|---|
| Disease progressionGeneral disorders | 0/6 | 0/6 | 0/6 | 1/6 | 2/6 | 0/6 | 0/5 |
| Soft tissue infectionInfections and infestations | 1/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 1/5 |
| Transient ischaemic attackNervous system disorders | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 1/5 |
| Neoplasm malignantNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 1/5 |
| Lung InfectionInfections and infestations | 1/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/5 |
| Clostridial infectionInfections and infestations | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 1/6 | 0/5 |
| ColitisGastrointestinal disorders | 0/6 | 1/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/5 |
| Abdominal painGastrointestinal disorders | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 1/6 | 0/5 |
| Oesophageal disorderGastrointestinal disorders | 0/6 | 0/6 | 0/6 | 1/6 | 0/6 | 0/6 | 0/5 |
| Abdominal pain lowerGastrointestinal disorders | 0/6 | 0/6 | 0/6 | 1/6 | 0/6 | 0/6 | 0/5 |
| Event | Omaveloxolone 5 mg & Ipilimumab | Omaveloxolone 10 mg & Ipilimumab | Omaveloxolone 5 mg & Nivolumab | Omaveloxolone 10 mg & Nivolumab | Omaveloxolone 20 mg & Nivolumab | Omaveloxolone 100 mg & Nivolumab | Omaveloxolone 150 mg & Nivolumab |
|---|---|---|---|---|---|---|---|
| FatigueGeneral disorders | 5/6 | 5/6 | 5/6 | 1/6 | 6/6 | 1/6 | 3/5 |
| DiarrhoeaGastrointestinal disorders | 3/6 | 3/6 | 1/6 | 1/6 | 2/6 | 4/6 | 2/5 |
| NauseaGastrointestinal disorders | 4/6 | 4/6 | 4/6 | 1/6 | 2/6 | 4/6 | 0/5 |
| PruritusSkin and subcutaneous tissue disorders | 4/6 | 3/6 | 2/6 | 1/6 | 2/6 | 0/6 | 0/5 |
| Nasal congestionRespiratory, thoracic and mediastinal disorders | 0/6 | 2/6 | 2/6 | 0/6 | 1/6 | 1/6 | 3/5 |
| Abdominal painGastrointestinal disorders | 0/6 | 3/6 | 2/6 | 2/6 | 1/6 | 1/6 | 0/5 |
| ConstipationGastrointestinal disorders | 1/6 | 2/6 | 3/6 | 3/6 | 3/6 | 0/6 | 1/5 |
| Upper respiratory tract infectionInfections and infestations | 3/6 | 0/6 | 1/6 | 0/6 | 0/6 | 2/6 | 1/5 |
| FallInjury, poisoning and procedural complications | 0/6 | 0/6 | 1/6 | 3/6 | 0/6 | 0/6 | 1/5 |
| Alanine aminotransferase increasedInvestigations | 3/6 | 2/6 | 2/6 | 1/6 | 0/6 | 1/6 | 1/5 |
| Age, Continuous(years) | Omaveloxolone 5 mg & Ipilimumab | Omaveloxolone 10 mg & Ipilimumab | Omaveloxolone 5 mg & Nivolumab | Omaveloxolone 10 mg & Nivolumab | Omaveloxolone 20 mg & Nivolumab | Omaveloxolone 100 mg & Nivolumab | Omaveloxolone 150 mg & Nivolumab | Total |
|---|---|---|---|---|---|---|---|---|
| Mean | 59.17 ± 18.713 | 53.5 ± 8.24 | 68.33 ± 12.42 | 51.67 ± 11.29 | 60.5 ± 13.882 | 65 ± 7.321 | 65 ± 5.958 | 60.3 ± 12.49 |
| Sex: Female, Male(Participants) | Omaveloxolone 5 mg & Ipilimumab | Omaveloxolone 10 mg & Ipilimumab | Omaveloxolone 5 mg & Nivolumab | Omaveloxolone 10 mg & Nivolumab | Omaveloxolone 20 mg & Nivolumab | Omaveloxolone 100 mg & Nivolumab | Omaveloxolone 150 mg & Nivolumab | Total |
|---|---|---|---|---|---|---|---|---|
| Female | 3 | 2 | 3 | 0 | 4 | 4 | 1 | 17 |
| Male | 3 | 4 | 3 | 6 | 2 | 2 | 4 | 24 |
| Ethnicity (NIH/OMB)(Participants) | Omaveloxolone 5 mg & Ipilimumab | Omaveloxolone 10 mg & Ipilimumab | Omaveloxolone 5 mg & Nivolumab | Omaveloxolone 10 mg & Nivolumab | Omaveloxolone 20 mg & Nivolumab | Omaveloxolone 100 mg & Nivolumab | Omaveloxolone 150 mg & Nivolumab | Total |
|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 2 |
| Not Hispanic or Latino | 6 | 6 | 5 | 5 | 6 | 6 | 5 | 39 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Omaveloxolone 5 mg & Ipilimumab | Omaveloxolone 10 mg & Ipilimumab | Omaveloxolone 5 mg & Nivolumab | Omaveloxolone 10 mg & Nivolumab | Omaveloxolone 20 mg & Nivolumab | Omaveloxolone 100 mg & Nivolumab | Omaveloxolone 150 mg & Nivolumab | Total |
|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| White | 6 | 6 | 6 | 6 | 6 | 6 | 5 | 41 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — In accordance with Biogen's Clinical Trial Transparency and Data Sharing Policy on https://www.biogentrialtransparency.com/
Data sharing details ↗ · vivli.org
Ran from Oct 2014 to primary completion in May 2018, 42 months.
Results were first posted in Jun 2021, 3 years 1 month after primary completion. A results delay was requested in May 2019.
Of 135 industry-sponsored phase 1/2 interventional studies under Melanoma, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 84. This study's 42 months is below that.
Counting every sponsor, half of 220 studies reached it within 61 months; a quarter within 42 and three quarters within 85.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Omaveloxolone